Purpose To provide recommendations on appropriate use of breast tumor biomarker assay
results to guide decisions on adjuvant systemic therapy for women with early-stage invasive …

Breast cancer is a complex disease encompassing multiple tumor entities, each
characterized by distinct morphology, behavior and clinical implications. Besides estrogen …

Abstract The 13th St Gallen International Breast Cancer Conference (2013) Expert Panel
reviewed and endorsed substantial new evidence on aspects of the local and regional …

The expression of Ki67 is strongly associated with tumor cell proliferation and growth, and is
widely used in routine pathological investigation as a proliferation marker. The nuclear …

Abstract The 12th St Gallen International Breast Cancer Conference (2011) Expert Panel
adopted a new approach to the classification of patients for therapeutic purposes based on …

The proliferation marker Ki-67 is one of the most controversially discussed parameters for
treatment decisions in breast cancer patients. The purpose of this study was to evaluate the …

Background In breast cancer, immunohistochemical assessment of proliferation using the
marker Ki67 has potential use in both research and clinical management. However, lack of …

A proliferative marker, expressed as the percentage of cells in a cell cycle, has been
developed and used as a discriminant of more aggressive malignant phenotypes in early …

The leading parameters that define treatment recommendations in early breast cancer are
oestrogen-receptor, progesterone-receptor, and human epidermal growth-factor status …

Purpose: According to current guidelines, molecular tests predicting the outcome of breast
cancer patients can be used to assist in making treatment decisions after consideration of …